Drug Approval | November 20, 2023
Teva announces approval of a generic version of Forteo in US
This approval showcases Teva’s proven strengths in complex generic formulations development and device engineering
This approval showcases Teva’s proven strengths in complex generic formulations development and device engineering
XTANDI becomes the first and only androgen receptor signaling inhibitor approved for use with or without a GnRH analog therapy in nonmetastatic castration-sensitive prostate cancer
Approval based on results from TOPAZ-1 global Phase III trial and a Chinese patient
Phase 3 data expected in the second half of 2024
Yesafili, received marketing authorization approval from the European Commission for the European Union
Digitally enabled drug discovery for oncology with potential to accelerate the delivery of new cancer therapies to patients
General Medicine grows 5% and Vaccines 10% led by Shingrix
We are redesigning Bayer to focus only on what’s essential for our mission, ‘Health for all, hunger for none’”
Lack of technology transfer stands out as a formidable barrier
Revenue in the three months ended on Oct. 1 also slipped by 42% to US$ 13.23 billion
Subscribe To Our Newsletter & Stay Updated
